- Home
- RNAZ vs NCNA Comparison
RNAZ vs NCNA Comparison
Compare RNAZ & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- NCNA
- Stock Information
- Founded
- RNAZ 2016
- NCNA 1997
- Country
- RNAZ United States
- NCNA United Kingdom
- Employees
- RNAZ N/A
- NCNA N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- NCNA Health Care
- Exchange
- RNAZ Nasdaq
- NCNA Nasdaq
- Market Cap
- RNAZ 6.1M
- NCNA 4.5M
- IPO Year
- RNAZ 2021
- NCNA 2017
- Fundamental
- Price
- RNAZ $8.69
- NCNA $0.05
- Analyst Decision
- RNAZ Strong Buy
- NCNA Buy
- Analyst Count
- RNAZ 1
- NCNA 2
- Target Price
- RNAZ $280.00
- NCNA $25.00
- AVG Volume (30 Days)
- RNAZ 27.7K
- NCNA 208.6M
- Earning Date
- RNAZ 08-13-2025
- NCNA 08-14-2025
- Dividend Yield
- RNAZ N/A
- NCNA N/A
- EPS Growth
- RNAZ N/A
- NCNA N/A
- EPS
- RNAZ N/A
- NCNA N/A
- Revenue
- RNAZ N/A
- NCNA N/A
- Revenue This Year
- RNAZ N/A
- NCNA N/A
- Revenue Next Year
- RNAZ N/A
- NCNA N/A
- P/E Ratio
- RNAZ N/A
- NCNA N/A
- Revenue Growth
- RNAZ N/A
- NCNA N/A
- 52 Week Low
- RNAZ $6.15
- NCNA $0.03
- 52 Week High
- RNAZ $905.52
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- RNAZ 52.45
- NCNA 38.50
- Support Level
- RNAZ $8.04
- NCNA $0.05
- Resistance Level
- RNAZ $9.70
- NCNA $0.13
- Average True Range (ATR)
- RNAZ 0.64
- NCNA 0.02
- MACD
- RNAZ 0.29
- NCNA 0.00
- Stochastic Oscillator
- RNAZ 57.26
- NCNA 4.62
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.